Anthem Biosciences Limited
Ghisallo bought 3,35,661 shares of Anthem Biosciences for ₹25.00 Cr at ₹744.80 apiece in a block deal. This was part of a larger transaction where a promoter sold a 3.05% stake and exited the company.
A biotechnology company providing contract research, development, and manufacturing services alongside specialty ingredients production. Established in 2006, the company serves pharmaceutical and nutraceutical sectors through its integrated CRDMO capabilities and custom synthesis expertise. Its distinctive position lies in combining comprehensive development expertise with in-house manufacturing facilities, enabling end-to-end solutions for clients requiring specialized ingredient formulation, process optimization, and commercial-scale production services.
Ghisallo Capital Management is a New York-based hedge fund investing in listed Indian equities.